Spinal fluid antibodies against multiple sclerosis candidate bacteria in demyelinating disease - Eckman, Emily; Laman, Jon D.; Fischer, Kael F.; Lopansri, Bert; Martins, Tom B.; Hill, Harry R.; Kriesel, John D. (medRxiv, 2021)
A panel of 10 IgG enzyme-linked immunosorbent assays (ELISAs) were developed for the detection of anti-microbial immune responses in the cerebrospinal fluid (CSF) of patients with demyelinating diseases (DD). Selection of the anti-microbial ELISA assays was guided by previous RNA sequencing studies that established a multiple sclerosis (MS) microbial candidate list. Microbial antigens included on the ELISA panel were derived from Akkermansia muciniphila, Atopobium vaginae, Bacteroides fragilis, Lactobacillus paracasei, Odoribacter splanchnicus, Pseudomonas aeruginosa, Cutibacterium (Propionibacterium) acnes, Fusobacterium necrophorum, Porphyromonas gingivalis, and Streptococcus mutans. Spinal fluid responses from patients with demyelinating diseases (DD, N=14) were compared to those with other neurological diseases (OND, N=8), and non-MS (Control, N=13) control patients. Commercial positive and negative control CSF specimens were run with each assay. ELISA Index values were derived for each specimen against each of the 10 bacterial antigen preparations. Intrathecal production of anti-microbial antibodies was assessed by comparing CSF and comparably diluted serum. CSF reactivity was significantly higher in the DD group compared to the controls against Akkermansia, Atopobium, Bacteroides, Lactobacillus, Odoribacter, and Fusobacterium. Four of the 11 tested DD group subjects had elevated antibody indexes against at least one of the 10 bacterial antigens, suggesting intrathecal production of anti-bacterial antibodies. This CSF serological study supports the hypothesis that several of the previously identified MS candidate microbes may contribute to demyelination in some patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by funds raised through the University of Utah School of Medicine. Author J.D.L. is supported by the Dutch MS Research Foundation (Voorschoten, The Netherlands) and the Zabawas Foundation (Den Haag, The Netherlands).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Utah Health Sciences IRB. Protocol 47316All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPrimary data files are retained by the first and senior authors.